Company / Net Income
Monte Rosa Therapeutics, Inc. Net Income History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$72.7M
FY2024
5-year range
-$135.4M / -$35.9M
FY2020-FY2024
Trend
+46.3%
vs FY2023
Sector context
#93 of 216
Health Care
What the data says
At -$73M, Monte Rosa Therapeutics, Inc.'s net income ranks #93 of 216 in the Health Care sector. Net Income returned to growth in FY2024 after 3 years of decline, reaching -$73M.
Based on SEC 10-K filings.
-$73M in FY2024.
Improved from -$109M to -$73M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#93 of 216 in Health CareTop 43% of 216This company -$72.7M Sector average $454.3M
▼
-116.0% below sector average
Key checks
Key Insights
- In FY2024, net income increased 46.3% year-over-year.
- Ranks #93 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2020.
- Lowest net income in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$72.7M | +46.3% |
| FY2023 | -$135.4M | -24.7% |
| FY2022 | -$108.5M | -46.7% |
| FY2021 | -$74.0M | -106.1% |
| FY2020 | -$35.9M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026